J Transl Med. 2015;13:339
IPM Biotech is now part of BioAgilytix! This partnership enhances and extends our rigor of science, service, and quality in Europe and beyond, to more easily support global studies for any large molecule need.
We are now able to offer customers on both continents ready access to top-caliber scientific expertise and technology. BioAgilytix’s U.S. headquarters is in the RTP area of North Carolina, and IPM Biotech’s Hamburg-based lab will act as our headquarters for work done in Europe.
While the IPM Biotech team continues operations at its current GLP laboratory, construction of a new, larger European laboratory facility is underway. The new site will enable IPM to significantly augment our current team of scientific experts, and more than triple our capacity, by the end of the year. We will also be adding GMP certification to this site in 2017.
IPM Biotech’s 20+ years of experience in assay development and validation work for immunogenicity, PK, and PD is a perfect complement to BioAgilytix’s breadth of best-of-breed large molecule bioanalytical capabilities. Together, we offer services for:
Explore the many peer-reviewed scientific publications authored by IPM Biotech co-founder Dr. Arno Jens Kromminga, a highly esteemed pioneer and leader in immunological assays.
To speak to IPM Biotech’s European headquarters, please use the following: